Update on Preferred Dividend Update on Preferred Dividend
See original here:
Dogecoin Cash, Inc. (OTC:CBDS) Announces Strategic Expansion of Crypto Holdings with Acquisition of 420 Million Dogecoin Cash ($DOG)
WARREN, N.J., Feb. 21, 2025 (GLOBE NEWSWIRE) -- Tevogen Bio (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech company, aims to set new efficiency standards in the industry, to prove that innovation and cost-effectiveness can coexist. Built with the rising cost of drug development in mind, Tevogen’s model aligns with current drug price reform efforts while challenging traditional biotech financing norms to ensure long-term sustainability.
Read the original:
Tevogen Bio’s First Trading Year Efficiency: 600% Higher Market Cap Per Team Member, 79% Insider-Owned
Fortrea and Starboard enter into Cooperation Agreement Fortrea and Starboard enter into Cooperation Agreement
Read more:
Fortrea to Add Erin L. Russell to Board of Directors
Monrovia, CA, Feb. 21, 2025 (GLOBE NEWSWIRE) -- eXoZymes Inc. (NASDAQ: EXOZ, formerly Invizyne Technologies) - a pioneer of AI-engineered enzymes that can transform sustainable feedstock into essential chemicals, medicines, and biofuels - and MDB Capital Holdings (NASDAQ: MDBH) - a premier venture platform for breakthrough technology companies - today announced key leadership changes within the eXoZymes board of directors.
Read the original post:
eXoZymes and MDB Capital Announce Leadership Transition at eXoZymes Inc.
Teva hosting investor call Monday, February 24 at 8:00 a.m. U.S. ET Teva hosting investor call Monday, February 24 at 8:00 a.m. U.S. ET
ECCO 2025: new duvakitug data reinforce best-in-class potential in ulcerative colitis and Crohn’s disease
Read the original here:
Press Release: ECCO 2025: new duvakitug data reinforce best-in-class potential in ulcerative colitis and Crohn’s disease
• Findings support the development of a novel peptide vaccine targeting the immunosuppressive effects of Transforming Growth Beta (TGF-?) in solid tumors
See original here:
IO Biotech Announces New Preclinical Data for Additional Pipeline Candidate Presented at the AACR-IO Conference
NEW YORK, Feb. 23, 2025 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that it has appointed Dr. Gregory George MD PhD, Mesoblast’s largest shareholder, to its Board of Directors.
Read the original here:
Dr. Gregory George MD PhD Joins Mesoblast Board
Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules
See the original post here:
Sandoz launches biosimilar Pyzchiva® (ustekinumab-ttwe) in the US, offering new treatment for around 12 million patients[1-4]
OSE Immunotherapeutics Reports Full Phase 2 Induction Results for Anti-IL-7R mAb Lusvertikimab in Ulcerative Colitis at the 20th Congress of ECCO
Here is the original post:
OSE Immunotherapeutics Reports Full Phase 2 Induction Results for Anti-IL-7R mAb Lusvertikimab in Ulcerative Colitis at the 20th Congress of ECCO
NEW YORK, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, showcases an innovative strategy for T cell engineering that leverages the pro-inflammatory properties of interleukin 2 (IL-2) with the objective to enhance CAR T cell efficacy against solid tumors, at the American Association for Cancer Research – Immuno-oncology (AACR-IO), taking place on February 23-26, 2025 in Los Angeles, CA.
Continue reading here:
Cellectis Presents ‘Smart CAR T’ Strategy to Enhance Efficacy Against Solid Tumors at AACR-IO 2025
The link you followed may be broken, or the page may have been moved.
To find the right page:
Once you find what you're looking for, please update your links or bookmarks.
You also may report the broken linkto the UNMC webmaster. Please include in your email the URL of the page where you clicked on the broken link. We need that URL in order to fix the broken link.
See the original post here:
What is Regenerative Medicine? | Regenerative Medicine | University of ...
Continued here:
AskBio Receives FDA Regenerative Medicine Advanced Therapy designation for Parkinsons disease investigational gene therapy - Bayer
Transforming the future of regenerative medicine Reuters
Read the rest here:
Transforming the future of regenerative medicine - Reuters
The quest for a communication device that tells cells to regenerate the body Big Think
Read the rest here:
The quest for a communication device that tells cells to regenerate the body - Big Think
Regenerative Medicine Pioneer with 35-Year Track Record Takes Scientific Helm at ZEO ScientifiX StockTitan
Tech Trends 2030: How AI, Quantum Computing, and Biotechnology Will Shape the Future Analytics Insight
View original post here:
Tech Trends 2030: How AI, Quantum Computing, and Biotechnology Will Shape the Future - Analytics Insight
Sustained in situ protein production and release in the mammalian gut by an engineered bacteriophage Nature.com
The rest is here:
Sustained in situ protein production and release in the mammalian gut by an engineered bacteriophage - Nature.com
Biotechnology Permits and Notifications USDA APHIS
Continued here:
Biotechnology Permits and Notifications - USDA APHIS